Effects of immunoglobulin on murine myocarditis caused by influenza A virus: Experimental study

Journal of Cardiology

Volumn 45, Issue 6, 2005, Pages 247-255

  Kishimoto, Chiharu ^a   Hiraoka, Yuji ^b   Takada, Hitoshi ^b   Kurokawa, Masahiko ^c   Ochiai, Hiroshi ^c  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Experimental medicine; Immunological factors (immunoglobulin); Myocarditis (influenza A virus)

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTRALIZING ANTIBODY; RECEPTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; IMMUNOTHERAPY; IN VITRO STUDY; INFLUENZA VIRUS A; INOCULATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SURVIVAL; TREATMENT OUTCOME; VIRUS MYOCARDITIS;

ANIMALS; CHEMOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS; MALE; MICE; MYOCARDITIS; MYOCARDIUM; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 21744459691     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Woodruff JF: Viral myocarditis: A review. Am J Pathol 1980; 101: 425-484
2. Reyes MP, Lerner AM: Coxsackievirus myocarditis: With special reference to acute and chronic effects. Prog Cardiovasc Dis 1985; 27: 373-394
3. Finland M, Parker JrF, Barnes MW, Joliffe CLS: Acute myocarditis in influenza A intections: Two cases of non-bacterial myocarditis, with isolation of virus from the lungs. Am J Med Sci 1945; 209: 455-468
4. Engblom E, Ekfors TO, Meurman OH, Toivanen A, Nikoskelainen J: Fatal influenza A myocarditis with isolation of virus from the myocardium. Acta Med Scand 1983; 213: 75-78
5. Takada H, Kishimoto C, Hiraoka Y: Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: Antiviral and anti-inflammatory effects. Circulation 1995; 92: 1604-1611
6. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW: Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257
7. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, Murali S, Feldman AM: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95: 2476-2478
8. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259
9. Ochiai H, Ikesue A, Kurokawa M, Nakajima K, Nakagawa H: Enhanced production of rat interleukin-8 by in vitro and in vivo infections with influenza A NWS virus. J Virol 1993; 67: 6811-6814
10. Sakai S, Kawamata H, Mantani N, Kogure T, Shimada Y, Terasawa K, Sakai T, Imanishi N, Ochiai H: Therapeutic effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice. J Virol 2000; 74: 2472-2476
11. Ochiai H, Sakai S, Kogure T, Hirabayashi Y, Nakajima K, Terasawa K: Development and some applications of enzyme linked immunosorbent assay system for murine macrophage inflammatory protein-2 (MIP-2). Mediat Inflamm 1996; 5: 206-209
12. Wolf HM, Eibl MM: Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol 1996; 14(Suppl 15): S17-S25
13. Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-228
14. Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H: Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol 2000; 36: 1979-1984
15. Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu TL, Feuerstein GZ: Interleukin-8: A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 1994; 75: 1-7
16. Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ: T lymphocyte recruitment by interleukin-8 (IL-8): IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996; 97: 1931-1941
17. Feng L, Xia Y, Yoshimura T, Wilson CB: Modulation of neutrophil influx in glomerulonephritis in the rat with antimacrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest 1995; 95: 1009-1017
18. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O: Requirement of MIP-1 α for an inflammatory response to viral infection. Science 1995; 269: 1583-1585
19. Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486
20. Shioji K, Kishimoto C, Sasayama S: Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: Concomitant suppression of the expression of dendritic cells. Circ Res 2001; 89: 540-546
21. Nemes E, Teichmah F, Roos D, Marodi L: Activation of human glanulocytes by intravenous immunoglobulin preparations is mediated by Fc γ R II and Fc γ RIII receptors. Pediatr Res 2000; 47: 357-361
22. Jodo S, Hohlbaum AM, Xiao S, Chan D, Strehlow D, Sherr DH, Marshak-Rothstein A, Ju ST: CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity. J Immunol 2000; 165: 5487-5494